- Home
- FEBO vs BOLT Comparison
FEBO vs BOLT Comparison
Compare FEBO & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | BOLT |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FEBO | BOLT |
|---|---|---|
| Price | $1.06 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 2.5K | ★ 27.0K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.61 | $0.26 |
| 52 Week High | $1.46 | $7.35 |
Technical Indicators
Market Signals| Indicator | FEBO | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 47.23 |
| Support Level | $1.04 | $4.33 |
| Resistance Level | $1.33 | $5.05 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 0.06 | 38.82 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.